Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis
Luciano Adorini(Intercept Pharmaceuticals (United States)), Mary Erickson(Intercept Pharmaceuticals (United States))
Cited by 8
Related Papers
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
|Gastroenterology|2014|563
Restructuring of the Gut Microbiome by Intermittent Fasting Prevents Retinopathy and Prolongs Survival in <i>db/db</i> Mice
|Diabetes|2018|385
FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity
|Journal of the American Society of Nephrology|2017|222
Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease
|Journal of Biological Chemistry|2013|218
G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes
|Journal of the American Society of Nephrology|2015|208